myriad
genetics
expands
board
directors
new
member
salt
lake
city
globe
newswire
myriad
genetics
nasdaq
mygn
myriad
company
global
leader
molecular
diagnostics
precision
medicine
today
announced
election
rashmi
kumar
age
board
directors
effective
immediately
expanding
board
members
additionally
kumar
appointed
audit
finance
committee
myriad
board
kumar
senior
vice
president
global
chief
information
officer
hewlett
packard
enterprise
company
previously
served
senior
vice
president
chief
information
officer
us
pharmaceutical
global
chief
data
officer
mckesson
corporation
kumar
received
bihar
institute
technology
university
california
irvine
rashmi
experience
expertise
transformation
ai
data
analytics
digital
solutions
drive
growth
transformational
business
outcomes
valuable
resource
myriad
said
paul
diaz
president
ceo
myriad
healthcare
experience
mckesson
oncology
pharmaceutical
businesses
also
instrumental
advancing
customer
focused
solutions
myriad
business
pleased
welcome
kumar
myriad
board
said
louise
phanstiel
chair
board
myriad
rashmi
perspective
experience
provide
important
strategic
insights
executing
global
strategy
molecular
diagnostics
precision
medicine
dynamic
changing
business
myriad
myriad
genetics
leading
precision
medicine
company
dedicated
trusted
advisor
transforming
patient
lives
worldwide
pioneering
molecular
diagnostics
myriad
discovers
commercializes
molecular
diagnostic
tests
determine
risk
developing
disease
accurately
diagnose
disease
assess
risk
disease
progression
guide
treatment
decisions
across
six
major
medical
specialties
molecular
diagnostics
significantly
improve
patient
care
lower
healthcare
costs
myriad
focused
three
strategic
imperatives
transitioning
expanding
hereditary
cancer
testing
markets
diversifying
product
portfolio
introduction
new
products
increasing
revenue
contribution
international
markets
information
myriad
making
difference
please
visit
company
website
myriad
myriad
logo
bart
bracanalysis
colaris
colaris
ap
mypath
myrisk
myriad
myrisk
myrisk
hereditary
cancer
mychoice
myplan
bracanalysis
cdx
tumor
bracanalysis
cdx
mychoice
cdx
vectra
prequel
foresight
genesight
riskscore
prolaris
trademarks
registered
trademarks
myriad
genetics
wholly
owned
subsidiaries
united
states
foreign
countries
safe
harbor
statement
press
release
contains
statements
within
meaning
private
securities
litigation
reform
act
including
statements
related
kumar
experience
expertise
valuable
resource
company
kumar
healthcare
experience
instrumental
advancing
customer
focused
solutions
company
business
partners
kumar
perspective
experience
providing
important
strategic
insights
executing
company
global
strategy
molecular
diagnostics
precision
medicine
dynamic
changing
business
environment
company
strategic
directives
caption
myriad
genetics
statements
based
management
current
expectations
future
events
subject
number
risks
uncertainties
could
cause
actual
results
differ
materially
adversely
set
forth
implied
statements
risks
uncertainties
include
limited
uncertainties
associated
including
possible
effects
operations
demand
products
services
ability
efficiently
flexibly
manage
business
amid
uncertainties
related
risk
sales
profit
margins
molecular
diagnostic
tests
pharmaceutical
clinical
services
may
decline
risks
related
ability
transition
existing
product
portfolio
new
tests
including
unexpected
costs
delays
risks
related
decisions
changes
governmental
private
insurers
reimbursement
levels
tests
ability
obtain
reimbursement
new
tests
comparable
levels
existing
tests
risks
related
increased
competition
development
new
competing
tests
services
risk
may
unable
develop
achieve
commercial
success
additional
molecular
diagnostic
tests
pharmaceutical
clinical
services
timely
manner
risk
may
successfully
develop
new
markets
molecular
diagnostic
tests
pharmaceutical
clinical
services
including
ability
successfully
generate
revenue
outside
united
states
risk
licenses
technology
underlying
molecular
diagnostic
tests
pharmaceutical
clinical
services
future
tests
services
terminated
maintained
satisfactory
terms
risks
related
delays
problems
operating
laboratory
testing
facilities
healthcare
clinic
risks
related
public
concern
genetic
testing
general
tests
particular
risks
related
regulatory
requirements
enforcement
united
states
foreign
countries
changes
structure
healthcare
system
healthcare
payment
systems
risks
related
ability
obtain
new
corporate
collaborations
licenses
acquire
new
technologies
businesses
satisfactory
terms
risks
related
ability
successfully
integrate
derive
benefits
technologies
businesses
license
acquire
risks
related
projections
business
results
operations
financial
condition
risks
related
potential
market
opportunity
products
services
risk
licensors
may
unable
protect
third
parties
infringe
proprietary
technologies
underlying
tests
risk
claims
challenges
validity
patents
intellectual
property
risks
related
changes
intellectual
property
laws
covering
molecular
diagnostic
tests
pharmaceutical
clinical
services
patents
enforcement
united
states
foreign
countries
supreme
court
decisions
mayo
collab
servs
prometheus
ass
n
molecular
pathology
myriad
genetics
alice
cls
bank
int
l
risks
new
changing
competitive
technologies
regulations
united
states
internationally
risk
may
unable
comply
financial
operating
covenants
credit
lending
agreements
risk
unable
pay
due
amounts
due
credit
lending
agreements
factors
discussed
heading
risk
factors
contained
item
recent
annual
report
form
fiscal
year
ended
june
filed
securities
exchange
commission
well
updates
risk
factors
filed
time
time
quarterly
reports
form
current
reports
form
information
press
release
date
release
myriad
undertakes
duty
update
information
unless
required
law
media
contact
jared
maxwell
investor
contact
scott
gleason
jmaxwell
sgleason
